

Polymyxins: “Last Resort” for MDR and/or XDR Gram-Negative Infections

Manal M. E. Ahmed¹

¹Pharmacology Department, Medical Research Division, National Research Centre, Egypt

Article Info

Article history:

Received: 11 May 2021

Revised: 28 July 2021

Accepted: 03 August 2021

Keywords:

polymyxins, polymyxin B, colistin, MDR Gram-negative infections, combination therapy

Paper Type :

Research Article

Correspondence Author

Manal M. E. Ahmed

Email:

thinktankteam2014@gmail.com

Abstract

Polymyxins were used for the management of gram-negative infections in clinical practice since 1940s. Parenteral administration waned in the seventies owing to polymyxins nephrotoxicity and neurotoxicity. Because of the lack of treatment choices for MDR and/or XDR gram negative superbugs as well as *Acinetobacter baumannii*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*, there is a growing need for effective prescribing of old antibiotics that are still effective. However, understanding of polymyxins pharmacokinetics (PK) was restricted and clinical experience is limited which leads to a lack of widespread availability of up-to-date dosing guidelines that could potentially result in the incorrect use of these “last resort” antibiotics. Recently, polymyxin B resistant strains are also a reason of concern. In this review, we discuss the importance of preserving the effectiveness of polymyxins for nosocomial gram-negative infections and strategies to improve polymyxins’ prescription. We recommend that polymyxins should only be used to manage significant MDR and/or XDR gram-negative infections, in optimum doses and if possible, in combination therapy

1. Introduction

Microbial resistance to antibiotics has a growing interest as it represents a vital issue for public health (Ventola, 2015; Hooton & Levy 2001). The resistance of Gram-negative bacteria (GNB) is of special concern for both bacteriologists and clinicians because of the fast-spreading of antibiotics resistance and the very limited treatment options (Shaikh *et al.*, 2015). It is worthy to mention that the fast spread of antibiotics resistance is not matched by the creation of novel promising molecules of antibiotics (Hooton & Levy, 2001). Therefore, there is a growing need for effective prescribing of old antibiotics that are still effective against multidrug and extremely drug-resistant (MDR and XDR) bacteria. International collaborative efforts are called to achieve this goal. In this concern, polymyxins is one of the frontline antibiotics which have not been used widely in the previous years (Theuretzbacher *et al.*, 2015). In the 1940s, polymyxins were approved for clinical use, while by the early 1970s, their severe side effects including severe nephrotoxicity and neurotoxicity limited their usage (Falagas *et al.*, 2005). Because of the lack of use in the last 50 years, pharmacodynamics (PD) of polymyxins is very limited. Recently, polymyxins have regained significant interest. Intravenous (iv) administration of these drugs has substantially increased in the last

decade due to their response in several infections caused by GNB especially the MDR bacteria such as *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, and *Klebsiella pneumoniae* has been significant (Gupta *et al.*, 2009). Growing usage of polymyxins in GNB infections was recognized and perceived in consensus for maximizing the clinical use of polymyxins “The Prato Polymyxin Consensus” (Nation *et al.*, 2015). Given the increasing use of polymyxin B in clinical settings. In this review, we discuss current usages of polymyxin B as monotherapy and in combinations and highlight the urgency of obtaining knowledge on their pharmacology to optimize their clinical usage and minimize the potential for bacterial resistance development.

Chemical structure of Polymyxins

Polymyxins group including polymyxin B and colistin (polymyxin E) is the “old” antibiotics that are clinically used. There has been a revived concern in this group of antibiotics because of their widespread resistance to newer antibiotics. Polymyxins are now labeled as (last resort” for MDR and/or XDR Gram-negative infections) (Kwa *et al.*, 2008). Although polymyxins were approved for clinical usage in the 1940s, they were not favored referring to their toxicities. However, their growing usage in critical care settings has helped for understanding their behavior in both Vitro and Vivo (Kwa *et al.*, 2008). The composition of polymyxins is a fatty acid chain (hydrophobic region) and amino acids (D and L) arranged in a cyclical heptapeptide ring. A tripeptide side chain binds the cyclical ring to the fatty acid chain. The single amino acid chain of D-leucine in polymyxin E is replaced by D-phenylalanine in polymyxin B (Figure 1) (Kwa *et al.*, 2008; Zavascki *et al.*, 2007; Landman *et al.*, 2008). The commercial form of polymyxin B is available as sulphate salt for parenteral administration (Kwa *et al.*, 2008). Different polypeptide components in polymyxin B including B1, B2, B3, and B1-I have different molecular formulas and the sum of these constitutes a minimum of 80% for polymyxin B. In concern of these components, there is batch to batch variation in commercial preparations (Kwa *et al.*, 2008).

The difference between polymyxin B and colistin is at R6. It is D-phenylalanine in polymyxin B and D-leucine in colistin. Forcolistinmethanesulphonate, there is the addition of a sulphomethyl group to the primary amines of colistin resulted in a change in the electrostatic charges. Thr: threonine; Leu: leucine; Phe: phenylalanine; Dab: diaminobutyric acid. CMS: colistin methanesulphonate (Deris *et al.* 2014).

Polymyxins mechanism of Action

Polymyxins' antimicrobial effect can be achieved by two mechanisms. Firstly, being positively charged, these cationic polypeptides interact electrostatically with bacterial lipopolysaccharide (LPS) that presents in GNB outer cell membrane. These interactions displace positively charged Ca ++ and Mg ++ (stabilizers of lipopolysaccharide in the outer cell membrane). This leads to instability of cell membrane-like detergent effect resulting in leakage of cell contents and accelerating bacterial death. Secondly, polymyxins have potent anti-endotoxin activity. Polymyxinsbinding to lipid A that is a component of LPS molecules neutralizing it. Whether the mechanism by which septic shock prevention occurs has not been understood yet. It is thought that plasma endotoxin is immediately bound by LPS-binding protein, and the complex is quickly bound to cell-surface CD14 (Gupta *et al.*, 2009; Kwa *et al.*,

2008). Another mechanism of bacterial killing by polymyxins involves inhibition of protein function has also been investigated. Deris *et al.*, (2014) explored that the type-II NADH-quinone oxidoreductase (NDH-2) is inhibited by polymyxin B as shown in figure (2) thus ubiquinone binding was competitively inhibited, and NADH was non-competitively inhibited by polymyxin B. The same finding has been proved in *Mycobacterium tuberculosis*. Despite the specific details of polymyxin-inducing bacterial killing still unknown, the primary interaction between polymyxins with lipid A is pivotal to the killing process; this is exemplified in the currently recognized resistance mechanisms.




Figure 2: Diagrammatic representation for polymyxins mechanism of action. Figure is adapted from Deris *et al.*, 2014.

- 1) Polymyxins target the outer membrane of Gram-negative bacteria.
- 2) The positively charged polymyxins displace divalent cations that bridge adjacent LPS molecules.
- 3) The electrostatic interaction weakens the stability of the outer membrane and the hydrophobic insertion destabilizes the outer membrane through hydrophobic expansion resulting in damage to the outer membrane.
- 4) Polymyxins penetrate the inner membrane and inhibit the respiratory enzyme NDH-2.

The spectrum of polymyxins:

The activity of polymyxin B is bactericidal mainly against Gram-negative bacteria such as *Enterobacter spp.*, *Pseudomonas aeruginosa*, *Acinetobacter spp.*, *Escherichia coli*, *Salmonella spp.*, *Klebsiella*, *Shigella spp.*, *Citrobacter spp.*, *Yersinia pseudotuberculosis*, *Haemophilus influenzae*, *Pasteurella spp.*, *Bordetella pertussis*, and *Legionella pneumophila*. Thus we can say that most nosocomial infections are susceptible to polymyxins (Kwa *et al.*, 2008; Landman *et al.*, 2008). However, some Gram-negative isolates are intrinsically resistant to polymyxins like *Burkholderia spp.*, *Proteus spp.*, *Providencia spp.*, *Morganella morganii*, and *Serratia spp.* Also, *Brucella spp.*, *Neisseria spp.*, and *Chromobacterium spp.* isolates are resistant. Both of Gram-positive bacteria and anaerobes are resistant to polymyxins [8,10]. While the minimal inhibitory concentrations (MIC₅₀ and MIC₉₀) are varied according to species of bacteria. For major susceptible GNB, MIC₅₀ and MIC₉₀ were ≤ 1 and 2 mg/L while for *Acinetobacter spp.*, ≤ 1 and > 8 mg/L for *Aeromonas spp.*, ≤ 1 and 2 mg/L for *P. aeruginosa*, ≤ 1 and ≤ 1 mg/L for *E. coli*, and ≤ 1 and ≤ 1 mg/L for *Klebsiella spp.* Respectively (Zavascki *et al.*, 2007). MIC₉₀ for most isolates of *B. cepacia*, *S. maltophilia*, *Proteus spp.*, *Proteus mirabilis*, *Serratia spp.*, and other enteric GNB was more than 8 mg/L because of the intrinsic resistance in these bacterial isolates (Zavascki *et al.*, 2007).

Resistance Mechanisms for polymyxins

Susceptibility breakpoints 2007, Clinical and Laboratory Standards Institute (CLSI) performed the susceptibility testing of polymyxins. For *Pseudomonas aeruginosa*, *Acinetobacter*, and *Enterobacteriaceae*, susceptibility breakpoints were as shown in table (1) (Zavascki *et al.*, 2007).

TABLE 1: Susceptibility breakpoints of polymyxins for major pathogens.

Organism	Profile		
	Susceptible	Intermediate	Resistant
CLSI recommendations [18]			
<i>P. aeruginosa</i> *	MIC ≤ 2 mg/L	MIC = 4	MIC ≥ 8 mg/L
<i>Acinetobacter spp.</i> *	MIC ≤ 2 mg/L	—	MIC ≥ 4 mg/L
Non-Enterobacteriaceae*	MIC ≤ 2 mg/L	MIC = 4	MIC ≥ 8 mg/L
BSAC Recommendations [19]			
<i>Pseudomonas spp.</i> †	MIC ≤ 4 mg/L	—	MIC ≥ 8 mg/L
<i>Enterobacteriaceae spp.</i> †	MIC ≤ 4 mg/L	—	MIC ≥ 8 mg/L

*For colistin and polymyxin B; †for colistin only. MIC: minimum inhibitory concentration; CLSI: Clinical and Laboratory Standards Institute; BSAC: British Society for Antimicrobial Chemotherapy.

The mechanisms

The mechanism of resistance involving preliminary alterations in interaction between polymyxin with bacterial LPS. Intrinsically resistant isolates of *Proteus mirabilis*, *Burkholderia cepacia*, and *Chromobacterium violaceum* developed modification in lipid A component of LPS in outer cell membrane resulting in a decrease in binding of polymyxins. The major modification noticed in LPS is that the 4-phosphate moiety of LPS is linked to 4-amino-4-deoxy-L-arabinopyranose making isolates resistant to polymyxins. Acquired resistance in *Salmonella spp.* and *E. coli* associated with reduced susceptibility to polymyxins

because of lipid A modification. Lipid A alteration with 4-amino-4-deoxy-L-arabinose (L-Ara4N) and/or phosphoethanolamine (PEtn) tends to reduce LOS negative charge which leads to reduced binding and increased resistance to polymyxins. Also, *K. pneumoniae* capsule is reported to be a potential factor for driving resistance (Zavascki *et al.*, 2007; Landman *et al.*, 2008). Additionally, in vitro, conditions of culture medium are found to be responsible for resistance to polymyxins (McLeod, G. I., & Spector, M. P. (1996).

Polymyxins pharmacokinetics

Although polymyxins have been applied clinically, understanding pharmacokinetics (PK) was only restricted for polymyxin B. Recently, the details of PK of polymyxins have been studied. Kwa *et al.* studied the PK of polymyxin B in MDR Gram-negative infections in adults ≥ 16 years without renal dysfunction. In a dose of 0.3 to 1 million units administered once or twice daily for a mean duration of 7 days, the reported mean volume of distribution (Vd) was 42.7 L with a half-life of 13.6 hours. Mean clearance was 2.4 L/h. This study leads to understanding PK of polymyxin B but its limitation was the small number ($n = 9$) of subjects (Kwa *et al.*, 2008). It was thought that polymyxin B doses should be adjusted according to the renal function (Gupta *et al.*, 2009) but a recent study by Sandri *et al.* (2013) provided enough details of population PK of polymyxin B in critically ill patients. Twenty-four patients (above 20 years) who had varying creatinine clearance administered polymyxin B in a dose of 0.45–3.38 mg/kg/day. They showed significantly low inter-individual variability in total body clearance when the dose was scaled by total body weight and not by total creatinine clearance. The coefficient of variation was 32.4%. Therefore, the authors concluded that polymyxin B clearance did not demonstrate any correlation with creatinine clearance even in patients who were on renal replacement therapy. They suggested that polymyxin B does not require modification of dose even in patients on renal replacement therapy. A large amount of filtered polymyxin B is reabsorbed from kidneys in a linear relationship with creatinine clearance suggesting higher reabsorption with declining renal function.

Furthermore, this study highlighted the dosing of polymyxin B according to MICs of causative organism, a high dose regimen (3 mg/kg/d) is necessary for $MIC \leq 2$ mg/L wherein loading dose should be considered. In less severe infection, for $MIC \leq 1$ mg/L, a usual dose of up to 2.5 mg/kg/d would be appropriate. For higher MICs, the dose must not exceed 3 mg/kg/d for safety concerns (Sandri *et al.*, 2013). In another small trial of 8 patients, PK data about polymyxin B revealed a peak plasma concentration of 2.38 to 13.9 mg/L at the end of a 1-hour intravenous (IV) infusion. Unchanged drug recovery in urine was 0.04%–0.86% of the dose. Other further studies proved that polymyxin B clearance is independent of renal function and is eliminated mainly by nonrenal pathways (Zavascki *et al.*, 2008).

Pharmacodynamics

Studies of polymyxin B based on the time-kill against different isolates of *P. aeruginosa*, *K. pneumoniae*, and *A. baumannii* showed concentration-dependent killing

(Landman *et al.*, 2008), which was followed by the regrowth of the isolates. These isolates were recorded to have higher MICs for polymyxin B. *P. aeruginosa* in vitro study with dosing interval in between 12 and 24 hours was associated with the emergence of resistant isolates comparing with shorter interval dosing (Tam *et al.*, 2005; Bergen *et al.*, 2008).

For this resistant development and reduction in susceptibility of such isolates, it is advisable to prescribe polymyxins in combination therapy. While usage of polymyxins in combinations in vitro studies has been reported to be associated with a reduction in regrowth of isolates, reduction in polymyxin B resistance and bactericidal activity even at sub-MIC concentrations of polymyxins. Although the evidence with polymyxins combinations clinically is still quite limited (Kwa *et al.*, 2008; Landman *et al.*, 2008).

Polymyxin B as Monotherapy

As described above, polymyxin B is composed of polypeptide components. These components were evaluated in vitro against three standard wild-type bacterial strains and three clinical MDR strains of *P. aeruginosa*, *A. baumannii*, and *K. pneumoniae*. Determination of MIC was performed using the dilution method in both. For potency, no substantial variations were noticed against standard and MDR strains suggesting that antibacterial activity has not been affected by molecular structure (Tam *et al.*, 2011). Also assessment of polymyxin B activity against carbapenem-resistant *A. baumannii* (CRAB) was performed by another study (Thamlikitkul *et al.*, (2014). For 217 clinical strains of CRAB, MIC₅₀ and MIC₉₀ values were 0.5 and 1 mg/L, respectively. With a breakpoint of ≤ 2 mg/L, 98.2% of strains were identified to be susceptible. These findings proved the efficacy of polymyxin B for CRAB infections. These results were supported by another Mexico study (Rosales-Reyes *et al.*, 2016) which demonstrated 100% susceptibility to highly lethal (mortality rate up to 28.2%) and biofilm-producing colonies (92.9% strains)—MDR *A. baumannii*—to polymyxin. Those were resistant to most antibiotics including aminoglycosides, cepheems, carbapenems, and fluoroquinolones. Thus we can conclude the superiority of polymyxin B efficacy against MDR and biofilm-producing *A. Baumannii* isolates.

From all of the above, we can consider polymyxin B as the last resort in MDR Gram-negative infections. In a retrospective analysis of critically ill children (≤ 15 years) with MDR Gram-negative infections (n = 14), polymyxin B administered in a dose of 40,000 IU/kg/day resulted in the survival of 57.1% of children. In addition, many clinical trials have been reported that the sensitivity of *Acinetobacter* spp., *P. aeruginosa*, *K. pneumoniae*, and *Enterobacter* spp. isolates reached up to 100% while nephrotoxicity was evident in three cases (Qamar *et al.*, 2014). Thus, polymyxin B was found as the modality to treat MDR Gram-negative infections. This calls for judicious use of polymyxins in critical cases. Kvitko *et al.* (2011) performed a retrospective evaluation for IV polymyxin B efficacy with a mean dose of 141 ± 54 mg, twice daily comparing to other antibiotics in patients with *P. aeruginosa* bacteraemia. In 133 patients (33.8% with polymyxin B and 66.2% with others; most common being beta-lactams (83%)), in-hospital mortality was observed to be significantly higher ($p \leq 0.001$) with polymyxin B (66.7%) than comparators (28.4%). Though mortality was higher with polymyxin B, optimize dosage utilization is crucial to reduce such outcomes. For preserving polymyxin B efficacy to susceptible strains, priority must be undertaken for decreasing or preventing the emergence of

resistance. Nelson *et al* (2015) Retrospective study evaluated the efficacy of polymyxin B for managing bloodstream infections caused by carbapenem-resistant Gram-negative rods (n = 151, *K. pneumoniae* 60.9%, *A. baumannii* 21.2%, and *P. aeruginosa* 11.3%). Overall 30-day mortality was 37.8%. 63.6% were found to have a clinical cure at day 7 of treatment. Post analysis shown a significant higher mortality with dose < 1.3 mg/kg/day (n = 0.02) but no difference observed in clinical cure at day 7 (n = 0.70). With a dose of 250 mg/d or more, acute kidney injury was noticed to be significantly greater (n = 0.03) which persisted in a multivariable analysis (odds ratio (OR) 4.32; n = 0.03).

In another similar study, Elias *et al.* (2010) concluded with the impact of polymyxin B dose on mortality outcome. In this retrospective assessment, patients (N = 276) receiving polymyxin B for over 72 hours were included and subgroup microbiological analysis confirmed infections and those with bacteraemia. The overall mortality rate was 60.5%. Septic shock (adjusted OR (aOR) 4.07), use of mechanical ventilation (aOR 3.14), Charlson comorbidity score (aOR 1.25), and age (aOR 1.02) were independent predictors of mortality. Polymyxin B in a dose of 200mg/day or above was associated with significantly lower mortality outcomes (aOR 0.43) and this effect was the same in both subgroups. On the other hand, this dose had a higher risk of severe renal impairment. These findings highlight the fact that a higher dosage of polymyxin B benefits in terms of reducing in-hospital mortality. This association needs further exploration in a large, prospective, randomized trial. Increased risk of renal injury calls for a careful look at coexisting factors that might contribute to renal damage. Therefore, targeting these factors may provide benefits in reducing the severity of renal injury accompanied with polymyxin B administration. The risk factors associated with polymyxin B monotherapy treatment failure in clinical cases (n = 40) of carbapenem-resistant *K. pneumonia* (CRKP) were retrospectively assessed by Dubrovskaya *et al.* (2013).

Clinical and microbiological cures were reported in 73% and 53 cases, respectively. Overall, the 30-day mortality reported was 28%. After adjusting for septic shock, baseline renal insufficiency was observed to be associated with a 6 times greater chance of clinical failure. Additionally, the observation of some breakthrough infections was intrinsically resistant to polymyxin B. Therefore, the leading cause of polymyxins failure as monotherapy may be regarding baseline renal dysfunction and subsequent development of resistant infections. Improving the efficacy and preventing the emergence of resistance in polymyxin B may be achieved by prescribing it in combination with other antibiotics.

Polymyxin B as Combination Therapy

It is recommended to use combination therapies for managing MDR and extremely drug-resistant (XDR) organisms including superbugs. In this scope of development of bacterial resistance, combination therapy with polymyxin B may be considered a promise for critically ill patients. Clinical usage of combination therapy may decrease the development of bacterial resistance in comparison to monotherapy (Bergen *et al.*, 2015). Synergistic efficacy of polymyxin B and chloramphenicol in MDRNDM-producing *K. pneumoniae* was observed by (Rahim *et al.* 2015). Chloramphenicol alone was ineffective with these strains and polymyxin B as monotherapy was also associated with rapid regrowth and emergence of resistance. Using critical care research and practice 5 combinations, no polymyxin-resistant isolates were

recorded. Scanning electron microscopy (SEM) features also were consistent with these findings. They found the formation of projections and blebs on the surface of bacterium which is consistent with the mechanism of polymyxin B and they were denser with combination treatment. This provides insights that combination treatment may avert the development of resistance to polymyxin B. This observation adds to the finding that antibiotics considered “old” can be beneficial even in superbug infections when used in combination.

One of the important nosocomial infections is carbapenem-resistant *A. baumannii* (CRAB) as combination therapies may prove beneficial effects. Three antibiotics—polymyxin B, rifampicin, and tigecycline were evaluated by Lim *et al.* (201) alone and in combination in such infections. Among 31 MDR isolates, all were susceptible to polymyxin B as monotherapy. Time-kill studies, no antibiotic had bactericidal activity. In combination, polymyxin and rifampicin shown the highest bactericidal activity (41.9%) followed by polymyxin and tigecycline (29.0%) and tigecycline and rifampicin (22.6%). Also, Hagihara *et al.* (2014) confirmed that polymyxin B and tigecycline (200 mg) resulted in a significantly greater reduction in bacterial density and the area under bacterial killing and regrowth curve (AUBC) comparing to polymyxin B monotherapy. Finally, the authors concluded that combination therapy is an effective tool for CRAB even with polymyxin B-sensitive infections.

Combination of minocycline and polymyxin B in *A. Baumannii* was evaluated by Bowers *et al.* (2015). The results revealed that polymyxin B improved intracellular penetration and thereby concentration of minocycline as well as enhanced in vitro bactericidal activity. This finding further proves the importance of combination treatment with polymyxin B. In another trial, the activity of polymyxin B in combination with imipenem, meropenem, or tigecycline in KPC-2 producing *Enterobacteriaceae* was assessed by Barth *et al.* (2015). Six strains including *K. Pneumonia* (n = 2), *Enterobacter cloacae* (n = 2), and *Serratia marcescens* (n = 2) had decreased susceptibility or resistant to polymyxin B and/or tigecycline and resistant to carbapenems. Polymyxin B in combination with carbapenem was most effective against *K. Pneumonia* and *Enterobacter cloacae* in comparison to the tigecycline combination. For *Serratia marcescens*, polymyxin B in combination with meropenem was highly effective and had synergistic bactericidal action.

In an extensively drug-resistant (XDR) *A. baumannii* (XDR-AB) study, polymyxin B in combination with imipenem, meropenem, doripenem, rifampicin, and tigecycline resulted in superior bactericidal activity compared to monotherapy. This suggests combination therapy must be considered in suspected XDR infections (Teo *et al.*, 2015). Data about polymyxin combination therapy are available from small, retrospective, observational studies while clinical studies are limited. Large, prospective, randomized studies are highly important to prove the benefits and the recommended optimal dosage (Bergen *et al.*, 2015). In an observational cohort study, polymyxin B in different combination therapies for carbapenem-resistant Gram-negative bacteria was evaluated by Crusio *et al.* (2014). Various infections included *A. baumannii* (n=34/104), *K. pneumonia* (n=25/104), *P. aeruginosa* (n=11/104), and other multiple organisms (n=34/105). Five cases showed bacteremia. They summarized clinical and microbiological success, hospital mortality, and 6-month mortality in five groups. No significant differences were recorded between groups in-hospital mortality as well as in 6-

month mortality outcome. Age, the severity of infection, and the Charlson score had a significant association with hospital mortality.

For XDRA. *Baumannii* or *P. aeruginosa* clinical cases, Rigatto *et al.* (2015) reported a significantly lower rate of 30-day mortality in combination therapy in comparison to polymyxin B alone (42.4% versus 67.6%, respectively, $n = 0.03$). Even in multivariate analysis, the combination treatment was reported to be independently associated with 30-day mortality. Specifically, the polymyxin B combination was useful with beta-lactams or carbapenems in *A. Baumannii* infections. *P. aeruginosa* associated mortality was significantly lower with the combination as compared to monotherapy ($n = 0.005$). Generally, data confirmed the superior efficacy of polymyxin B-based combination therapy in treating MDR and XDR Gram-negative infections. In addition, the prescription of a validated polymyxin combination therapy based on multiple combination bactericidal testing was found superior to nonvalidated combination therapy and polymyxin monotherapy in decreasing mortality for cases suffering from XDR Gram-negative infections (Cai *et al.*, 2016). While testing bactericidal activity of combination agents and thereafter combining these agents can reduce infection-related mortality, the empiric combination should not be delayed in a critical setting that can be further modified after sensitivity testing.

Polymyxins synergy with antifungals

Additionally, polymyxins are exhibiting weak fungicidal properties (MIC = 8 mg/L). This synergistic antifungal activity of polymyxin B was studied as early as 1972. For example, polymyxin B potentiates the activity of tetracycline against *Candida albicans* and *Saccharomyces cerevisiae*, even at low concentrations. It seemed that polymyxins increase the permeability of the yeast Cell membrane to tetracycline, which inhibited protein synthesis resulting in cell death (Schwartz *et al.*, 1972). A more recent study showed that combinations of polymyxin B with fluconazole or itraconazole are more effective even at low concentrations against *Aspergillus fumigatus*, *Rhizopus oryzae*, *Candida albicans* and non-*albicans* *Candida* species. These combinations at clinically relevant low concentrations were particularly potent against *Cryptococcus neoformans*, involving resistance strains to fluconazole (Zhai *et al.*, 2010). Polymyxin B has also been decreased the tissue fungal burden both in intravenous and inhalation models of murine cryptococcosis at a level comparable to that of fluconazole (Zhai & Lin, (2013).

Synergistic antifungal activity against *C. albicans* has also been achieved when both of polymyxin B and colistin were combined with amphotericin B, ketoconazole and miconazole against *R. oryzae* (Pietschmann *et al.*, 2009). Both as a single agent and in combination with voriconazole, caspofungin and amphotericin B, has also shown antifungal activity in vitro against filamentous *ascomycetes* causing cystic fibrosis in patients. This activity may provide a new therapeutic approach, especially for *MDRS cedosporium prolificans* (Schemuth *et al.*, 2013).

Recently, susceptibility of 25 clinical isolates of *Fusarium* to antifungal agents including amphotericin B, caspofungin, itraconazole, voriconazole, and antimicrobials pentamidine B, tigecycline and tobramycin was evaluated in vitro. Amphotericin B or voriconazole in combination with tobramycin showed the highest rates of synergism (80% and

76%, respectively) followed by polymyxin B (76% and 64%) and pentamidine (72% and 68%) (Venturini *et al.*, 2016; Hsu *et al.*, 2017). Also, caspofungin and echinocandin antifungals when combined with colistin have been shown to act synergistically against fluconazole-resistant and susceptible *C. albicans* and *C. glabrata* isolates. The authors also mentioned that the correlation with in vivo benefits may not be straightforward (Adams, *et al.*, 2016; Pankey *et al.*, 2014; Zeidler *et al.*, 2013).

Antibiofilm activity

The biofilm is considered as an organized microbial ecosystem, consisting of one or more microbial species which are embedded in a self-produced matrix of extracellular polymeric substances that contain proteins, polysaccharides and DNA. Biofilms may appear on the body tissues as well as the surfaces of medical devices. Management of these biofilms mostly needs a high dose of antibiotics administered for a long time. Polymyxins have been proven to be effective against biofilms, alone or in combination therapy specifically against *A. baumannii* and *P. aeruginosa* (Gopal *et al.*, 2014; Lora-Tamayo *et al.*, 2014). However, neither colistin nor polymyxin B were able to prevent (p)ppGpp accumulation (alarmones guanosine 5'-diphosphate 3'-diphosphate, ppGpp, and guanosine 5'-triphosphate 3'-diphosphate, pppGpp), signaling nucleotides that regulate the stringent response in bacteria and which are thought to play a vital role in the formation of biofilm (de la Fuente-Núñez *et al.*, 2014).

Polymyxins were examined for showing an antibiofilm synergistic interaction with cyclic antimicrobial peptide gramicidin S toward 17 multidrug-resistant *P. aeruginosa* and biofilms of *P. aeruginosa* strain PAO1. The required concentration of Polymyxin B for inhibition of biofilm formation by *P. aeruginosa* PAO1 was 8 mg/mL while treatment with gramicidin S as combination therapy required only 2 mg/mL. Also, gramicidin S concentration was reduced from 32 mg/mL to 4 mg/mL in this combination. The fractional inhibitory concentration (FIC) calculated from this decrease was 0.375, which indicated the synergistic effect of this treatment (Berditsch *et al.*, 2015). Inhibition of biofilm formation by *P. aeruginosa* PAO1 strain has also been established. Antimicrobials that inhibit biofilm formation such as colistin and tobramycin, both alone and in combination, demonstrated bactericidal effect before biofilm attachment to endotracheal tubes while there is no activity was noticed once the biofilm formed on such polyvinylchloride tubes (Tarquinio *et al.*, 2014). It is proved that polymyxin B is 100% effective in vitro against a highly prevalent clone of multi-drug resistant *A. baumannii*, with 92.9% of strains being biofilm producers. However, no direct proof of polymyxin inhibiting biofilm formation in this clone was recorded (R. Rosales-Reyes *et al.*, 2015).

Recently, colistin entrapped in nanoparticles of different materials, [poly (lactide-co-glycolide), chitosan and poly (vinyl alcohol)], has been found to eradicate pre-formed *P. aeruginosa* biofilms. Nanoparticles of colistin/poly (vinyl alcohol) and colistin/chitosan could penetrate inside the biofilms and release colistin in situ, thus increasing the effectiveness of the therapies (d'Angelo *et al.*, (2015). An additive or synergistic effect between colistin and levofloxacin has been established in vitro and in a *Galleria mellonella* model against colistin-susceptible *A. baumannii* strains but not against colistin-resistant strains (Wei *et al.*, 2015).

Polymyxins clinical Safety

Nephrotoxicity

It is a well-known side effect of polymyxins. Most previous studies and case reports reported its high incidence of nephrotoxicity but with no specific definition of renal dysfunction. It was regarded mainly as intramuscular administration. Polymyxin B was identified to be associated with a higher incidence of renal toxicity comparing to colistin/colistimethate sodium. Recently, lower nephrotoxicity rates have been recorded even with polymyxin B. The suggested mechanism of renal dysfunction caused by polymyxin B is happened by increasing membrane permeability that leads to cell swelling due to the influx of water and ions that resulted in cell death. Additionally, fatty acid and amino acid components of polymyxin B are considered to be responsible for cell injury. Polymyxins nephrotoxicity is dose-dependent (Falagas & Kasiakou, 2006). Briefly, recent studies of polymyxin B associated nephropathy is discussed below.

Ouderkirk *et al.* (20013) reported a 14% prevalence of ARF in patients treated with polymyxin B (n = 60). Those who developed ARF were older (mean age of 76 versus 59 years, $p = 0.02$). Higher mortality rate was reported (57% versus 15%, $p < 0.02$) in ARF cases. Similarly, Holloway *et al.* (2006) reported ARF in 21.2% (n=7/33) patients. None of the ARF required dialysis and creatinine levels returned to the normal range with discontinuation of polymyxin B in 71.4 % (n=5/7) cases. Furtado *et al.* (2007) reported nephrotoxicity in 9.4% of patients with *P. aeruginosa* associated nosocomial pneumonia treated with polymyxin B. Also, there was no difference in ARF occurrence in patients who had favorable or unfavorable results.

Few studies were performed to recognize the factors associated with renal dysfunction due to polymyxin B. Bahlis *et al.* (2015) in a retrospective cohort study identified 43% of patients of renal injury by RIFLE (Risk, Injury, and Failure; Loss; and end-stage kidney disease) criteria. They observed hypotension (OR 2.79; $p = 0.006$) and concomitant vancomycin use (OR 2.79; $p = 0.011$) as independent predictors of renal injury. Similarly, Dubrovskaya *et al.* (2015) in a retrospective cohort study evaluated 192 patients who received polymyxin B for more than 72 hours. In a mean duration of 9.5 days of treatment, the renal injury was found in 45.8% of patients. They reported daily dose based on actual weight (hazard ratio (HR) 1.73, $p = 0.022$), concomitant vancomycin (HR 1.89, $p = 0.005$), and use of contrast media (HR 1.79, $p = 0.009$) as independent risk factors for nephrotoxicity. In another multicenter, retrospective cohort study, a comparison of nephrotoxicity rates between colistimethate sodium (n = 121) and polymyxin B (n = 104) was tried by Phe *et al.* (2014) to validate their findings of in vitro cytotoxicity study. Patients administering polymyxin B for more than 72 hours who had normal kidney function were assessed.

In risk factors matched analysis, observed rates of nephrotoxicity were significantly ($p = 0.004$) higher with colistimethate sodium (55.3%) in comparison to polymyxin B (21.1%). On a multivariate analysis, significant and independent association of renal toxicity due to colistimethate was recorded with age (OR: 1.04, 95% CI, 1.00, 1.07), treatment duration (OR: 1.08, 95% CI, 1.02, 1.15), and daily dose based on body weight (OR: 1.40, 95% CI, 1.05, 1.88). A prospective comparison between two polymyxins is required for further substantiation of this finding. A prospective cohort evaluation from Rigatto *et al.* (2015) in 410 patients

administering polymyxin B for more than 48 hours reported acute renal toxicity in 46.1% of cases. Dose of polymyxin ≥ 150 mg/day was significantly associated with renal dysfunction (HR 1.95, $p = 0.01$). It is of interest to show that the increased risk was maximal for dose range from 150 to 199 mg/day and no further significant increase was observed for even higher doses. They found renal injury as an independent predictor of 30-day mortality (HR 1.35, $p = 0.06$) while the dose over 150 mg/day did not increase mortality. This paradox calls for careful patient assessment. A higher dose may be associated with mortality but simultaneous renal dysfunction is increased. Exploring the underlying predisposing factors such as hypotension, use of vancomycin, or any contrast media is necessary. Modification of these abnormalities might assist in decreasing the incidence of renal injury with polymyxin B. In this scope, Rigatto *et al.* (2016) (Falagas & Kasiakou, 2006). Studied mortality outcomes in patients of renal replacement therapy (RRT). In 88 RRT patients administering polymyxin B (1.5 to 3 mg/kg/day) for more than 48 hours, 30-day mortality was 51.1%. A daily dose above 200 mg was associated with lower mortality (HR 0.35, $n = 0.03$). Therefore, a higher dose is effective in lowering mortality even in RRT cases.

Neurotoxicity

The incidence of neuropathy because of polymyxins administration is about 7%. Its symptoms are similar to any other neuropathy including weakness, paraesthesia, ophthalmoplegia, dysphagia, ataxia, and neuromuscular weakness sometimes resulting in respiratory failure. Colistin/colistimethate sodium are mostly induced neurotoxicity (Falagas & Kasiakou, 2006). However, no severe forms of neurotoxicity necessitating respiratory support have been recorded in the last twenty years (Zavascki *et al.* (2006) identified one case of new-onset altered mental status and one with distal paraesthesia.

Neuropathy manifesting as seizures and neuromuscular weakness which were possibly due to polymyxin B in two (7%) cases was studied by Sobieszczyk *et al.* (2004). Recently two cases of polymyxin B-induced neuropathy were reported by Weinstein *et al.* (2009). The first case was a 60-year-old obese diabetic female with other multiple ailments and was on treatment with multiple medications including varenicline and quetiapine. Polymyxin B loading dose was 20000 U/Kg in two divided doses. It was initiated for *K. Pneumonia* identified in urine culture that was only sensitive to polymyxin B. She developed oral paraesthesia within 1 hour of starting IV infusion. The second patient was a 57-year-old male having ascending cholangitis. MDR *K. pneumonia* susceptible only to polymyxin B, gentamicin, and trimethoprim-sulfamethoxazole was found in drain fluid culture. Multiple medications were prescribed during hospitalization. For pancreatic abscess, the patient was advised with 30-day treatment with polymyxin B and imipenem cilastatin. After 30 days, oral and lower extremity paraesthesia were occurring but symptoms reversed with discontinuation of polymyxin B. There was no rechallenge attempted in either case. Although it is not commonly reported, caution is necessary with increasing doses of polymyxin B for monitoring neurotoxicity.

Congenital Anomalies

It is rarely reported with polymyxin Kazy *et al.* (2005) recorded crude OR of 0.8 for the first trimester. Anomalies involving cardiovascular malformations, neural tube defect,

microcephaly, limb reduction defect, and congenital talipes equinovarus are recorded. Because of the small number of cases, the risk appears small though existent. In general, there is limited data for polymyxin B and assessment in a larger sample is important to confirm the causal effect (Zavascki *et al.*, 2007).

Tolerability of polymyxin B

In general, polymyxin B is well tolerated (Zavascki, (2011). Milder side effects may include rash, pruritus, dermatitis, and fever. They are probably the result of the histamine-releasing action of polymyxin B (Zavascki *et al.*, 2007).

Dosage and Administration of Polymyxin B

The recommended daily dose of polymyxin B is 1.5 to 2.5 mg/kg in common. It is administered IV in two divided doses as a one-hour infusion. This dose is well-tolerated in an empirical setting (Zavascki *et al.*, 2007). Some studies suggest a dose of up to 3 mg/kg/day being used in a clinical setting (Sandri *et al.*, 2013; Zavascki *et al.*, 2008)). Evidence suggests that a daily dose of 200 mg and above is associated with better mortality outcomes as we mention above, however, the renal injury requires to be cautiously monitored at such higher dose. Therefore, doses above 3 mg/kg/day cannot be recommended for safety concerns (Sandri *et al.*, 2013). Evaluation of baseline renal function may be important but dosing is not affected by renal function as polymyxin B is majorly eliminated by non-renal mechanisms. Prescribing polymyxin B in an adequate dosage is essential to avoid underdosing in lieu of renal dysfunction (Zavascki, 2011; Kwa *et al.*, 2011).

Positioning polymyxins in therapy

Recently, polymyxin B has reemerged in a clinical setting. Its use is likely to continue to increase since new drugs for the treatment of infections caused by MDR Gramnegative bacteria are beyond a distant horizon. Therefore, we can consider polymyxin B as the last resort therapy for MDR and XDR Gram-negative infections particularly those caused by *K. pneumoniae*, *A. baumannii*, and *P. aeruginosa*. PK data have made understanding of polymyxin B kinetics more clear. Also, it helps explore dosing regimens. Dosing based on actual body weight is helpful and should not be based on renal function. Efficacy against superbugs producing NDM-1 beta-lactamases makes polymyxin B crucial in infection management. IV administration has been most effective in improving clinical, microbiological, and mortality outcomes not only in adults but in critically ill children also. Initial dose selection and titration are simple and more predictable for polymyxin B because of smaller interindividual variability and lack of impact of renal function on drug clearance. Therapeutic drug monitoring for polymyxin B lacks the significant difficulties that exist for colistin (Nation *et al.*, 2014).

2. Conclusion

Maintaining polymyxins efficiency in the era of resistant superbugs is a critical and vital issue to extend its clinical use. Currently, polymyxins are the last resort for most MDR

and/or XDR Gram-negative infections including *A. baumannii*, *K. pneumoniae* and *P. aeruginosa*. Thus understanding of polymyxins PK and PD is a very important issue for optimization of their usage. Validated or even empiric combinations of polymyxins with other antibiotics is recommended for avoiding treatment failure, reduce infection-related mortality and prevent the emergence of resistance.

References

- Abdul Rahim, N., Cheah, S. E., Johnson, M. D., Yu, H., Sidjabat, H. E., Boyce, J., ... & Li, J. (2015). Synergistic killing of NDM-producing MDR *Klebsiella pneumoniae* by two 'old' antibiotics—polymyxin B and chloramphenicol. *Journal of Antimicrobial Chemotherapy*, 70(9), 2589-2597.
- Bahlis, L. F., Diogo, L. P., Lemons, D., & Klaus, D. (2015). Risk factors for acute kidney injury in patients treated with polymyxin B at a Tertiary Care Medical Center. *Brazilian Journal of Nephrology*, 37, 446-450.
- Barth, N., Ribeiro, V. B., & Zavascki, A. P. (2015). In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials. *Antimicrobial agents and chemotherapy*, 59(6), 3596-3597.
- Ben-Ami, R., Lewis, R. E., Tarrand, J., Leventakos, K., & Kontoyiannis, D. P. (2010). Antifungal activity of colistin against Mucorales species in vitro and in a murine model of *Rhizopus oryzae* pulmonary infection. *Antimicrobial agents and chemotherapy*, 54(1), 484-490.
- Berditsch, M., Jäger, T., Stempel, N., Schwartz, T., Overhage, J., & Ulrich, A. S. (2015). Synergistic effect of membrane-active peptides polymyxin B and gramicidin S on multidrug-resistant strains and biofilms of *Pseudomonas aeruginosa*. *Antimicrobial agents and chemotherapy*, 59(9), 5288-5296.
- Bergen, P. J., Bulman, Z. P., Saju, S., Bulitta, J. B., Landersdorfer, C., Forrest, A., ... & Tsuji, B. T. (2015). Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 35(1), 34-42.
- Bergen, P. J., Li, J., Nation, R. L., Turnidge, J. D., Coulthard, K., & Milne, R. W. (2008). Comparison of once-, twice-and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with *Pseudomonas aeruginosa* in an in vitro pharmacodynamic model. *Journal of Antimicrobial Chemotherapy*, 61(3), 636-642.
- Bowers, D. R., Cao, H., Zhou, J., Ledesma, K. R., Sun, D., Lomovskaya, O., & Tam, V. H. (2015). Assessment of minocycline and polymyxin B combination against *Acinetobacter baumannii*. *Antimicrobial agents and chemotherapy*, 59(5), 2720-2725.
- C. de la Fuente-Núñez, F. Reffuveille, E. F. Haney, S. K. Straus and R. E. Hancock, *PLoS Pathog.*, vol. 10, e1004152, 2014.
- Cai, B., Cai, Y., Liew, Y. X., Chua, N. G., Teo, J. Q. M., Lim, T. P., ... & Kwa, A. L. H. (2016). Clinical efficacy of polymyxin monotherapy versus nonvalidated polymyxin combination therapy versus validated polymyxin combination therapy in extensively

- drug-resistant Gram-negative bacillus infections. *Antimicrobial agents and chemotherapy*, 60(7), 4013-4022.
- Crusio, R., Rao, S., Changawala, N., Paul, V., Tiu, C., van Ginkel, J., ... & Kupfer, Y. (2014). Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. *Scandinavian journal of infectious diseases*, 46(1), 1-8.
- Deris, Z. Z., Akter, J., Sivanesan, S., Roberts, K. D., Thompson, P. E., Nation, R. L., ... & Velkov, T. (2014). A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. *The Journal of antibiotics*, 67(2), 147-151.
- Dubrovskaya, Y., Chen, T. Y., Scipione, M. R., Esaian, D., Phillips, M. S., Papadopoulos, J., & Mehta, S. A. (2013). Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant *Klebsiella pneumoniae* infections. *Antimicrobial agents and chemotherapy*, 57(11), 5394-5397.
- Dubrovskaya, Y., Prasad, N., Lee, Y., Esaian, D., Figueroa, D. A., & Tam, V. H. (2015). Risk factors for nephrotoxicity onset associated with polymyxin B therapy. *Journal of Antimicrobial Chemotherapy*, 70(6), 1903-1907.
- Elias, L. S., Konzen, D., Krebs, J. M., & Zavascki, A. P. (2010). The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. *Journal of antimicrobial chemotherapy*, 65(10), 2231-2237.
- Falagas, M. E., & Kasiakou, S. K. (2006). Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. *Critical care*, 10(1), 1-13.
- Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005). Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. *Clinical infectious diseases*, 40(9), 1333-1341.
- Furtado, G. H. C., d'Azevedo, P. A., Santos, A. F., Gales, A. C., Pignatari, A. C. C., & Medeiros, E. A. S. (2007). Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant *Pseudomonas aeruginosa*. *International journal of antimicrobial agents*, 30(4), 315-319.
- Gopal, R., Kim, Y. G., Lee, J. H., Lee, S. K., Chae, J. D., Son, B. K., ... & Park, Y. (2014). Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant *Acinetobacter baumannii* strains. *Antimicrobial agents and chemotherapy*, 58(3), 1622-1629.
- Groisman, E. A., Kayser, J., & Soncini, F. C. (1997). Regulation of polymyxin resistance and adaptation to low-Mg²⁺ environments. *Journal of bacteriology*, 179(22), 7040-7045.
- Gupta, S., Govil, D., Kakar, P. N., Prakash, O., Arora, D., Das, S., ... & Malhotra, A. (2009). Colistin and polymyxin B: a re-emergence. *Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine*, 13(2), 49.
- Hagihara, M., Housman, S. T., Nicolau, D. P., & Kuti, J. L. (2014). In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant *Acinetobacter baumannii*. *Antimicrobial agents and chemotherapy*, 58(2), 874-879.

- Holloway, K. P., Roupael, N. G., Wells, J. B., King, M. D., & Blumberg, H. M. (2006). Polymyxin B and doxycycline use in patients with multidrug-resistant *Acinetobacter baumannii* infections in the intensive care unit. *Annals of Pharmacotherapy*, 40(11), 1939-1945.
- Hooton, T. M., & Levy, S. B. (2001). Antimicrobial Resistance: A Plan of Action for Community Practice. *American family physician*, 63(6), 1087.
- Hsu, L. H., Wang, H. F., Sun, P. L., Hu, F. R., & Chen, Y. L. (2017). The antibiotic polymyxin B exhibits novel antifungal activity against *Fusarium* species. *International journal of antimicrobial agents*, 49(6), 740-748.
- I. d'Angelo, B. Casciaro, A. Miro, F. Quaglia, M. L. Mangoniand F. Ungaro, *Colloids Surf., B*, vol. 35, pp. 717–725, 2015.
- Kazy, Z., Puho, E., & Czeizel, A. E. (2005). Parenteral polymyxin B treatment during pregnancy. *Reproductive toxicology (Elmsford, NY)*, 20(2), 181-182.
- Kvitko, C. H., Rigatto, M. H., Moro, A. L., & Zavascki, A. P. (2011). Polymyxin B versus other antimicrobials for the treatment of *Pseudomonas aeruginosa* bacteraemia. *Journal of Antimicrobial Chemotherapy*, 66(1), 175-179.
- Kwa, A. L., Abdelraouf, K., Low, J. G., & Tam, V. H. (2011). Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. *Clinical Infectious Diseases*, 52(10), 1280-1281.
- Kwa, A. L., Lim, T. P., Low, J. G., Hou, J., Kurup, A., Prince, R. A., & Tam, V. H. (2008). Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. *Diagnostic microbiology and infectious disease*, 60(2), 163-167.
- Kwa, A. L., Tam, V. H., & Falagas, M. E. (2008). Polymyxins: a review of the current status including recent developments. *Ann Acad Med Singapore*, 37(10), 870-883.
- Landman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008). Polymyxins revisited. *Clinical microbiology reviews*, 21(3), 449-465.
- Lim, T. P., Tan, T. Y., Lee, W., Sasikala, S., Tan, T. T., Hsu, L. Y., & Kwa, A. L. (2011). In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant *Acinetobacter baumannii* in Singapore. *PloS one*, 6(4), e18485.
- Lora-Tamayo, J., Murillo, O., Bergen, P. J., Nation, R. L., Poudyal, A., Luo, X., ... & Li, J. (2014). Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant *Pseudomonas aeruginosa* in an in vitro dynamic biofilm model. *Journal of antimicrobial chemotherapy*, 69(9), 2434-2442.
- McLeod, G. I., & Spector, M. P. (1996). Starvation-and Stationary-phase-induced resistance to the antimicrobial peptide polymyxin B in *Salmonella typhimurium* is RpoS (sigma (S)) independent and occurs through both *phoP*-dependent and-independent pathways. *Journal of Bacteriology*, 178(13), 3683-3688.
- Nation, R. L., Li, J., Cars, O., Couet, W., Dudley, M. N., Kaye, K. S., ... & Turnidge, J. D. (2015). Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. *The Lancet infectious diseases*, 15(2), 225-234.
- Nation, R. L., Velkov, T., & Li, J. (2014). Colistin and polymyxin B: peas in a pod, or chalk and cheese?. *Clinical infectious diseases*, 59(1), 88-94.

- Nelson, B. C., Eiras, D. P., Gomez-Simmonds, A., Loo, A. S., Satlin, M. J., Jenkins, S. G., ... & Kubin, C. J. (2015). Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. *Antimicrobial agents and chemotherapy*, 59(11), 7000-7006.
- Ouderkirk, J. P., Nord, J. A., Turett, G. S., & Kislak, J. W. (2003). Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. *Antimicrobial agents and chemotherapy*, 47(8), 2659-2662.
- Pankey, G., Ashcraft, D., Kahn, H., & Ismail, A. (2014). Time-kill assay and Etest evaluation for synergy with polymyxin B and fluconazole against *Candida glabrata*. *Antimicrobial agents and chemotherapy*, 58(10), 5795-5800.
- Phe, K., Lee, Y., McDanel, P. M., Prasad, N., Yin, T., Figueroa, D. A., ... & Tam, V. H. (2014). In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. *Antimicrobial agents and chemotherapy*, 58(5), 2740-2746.
- Pietschmann, S., Hoffmann, K., Voget, M., & Pison, U. (2009). Synergistic effects of miconazole and polymyxin B on microbial pathogens. *Veterinary research communications*, 33(6), 489.
- Qamar, F. N., Jurair, H., & Haque, A. (2014). Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. *BMC infectious diseases*, 14(1), 1-7.
- R. Rosales-Reyes, M. D. Alcántara-Curiel, M. D. Jarillo-Quijada, C. Gayosso-Vázquez, M. Morfin-Otero, E. Rodríguez-Noriega and J. Santos-Preciado, *Chemotherapy*, vol. 61, pp. 8–14, 2015–2016.
- Rigatto, M. H., Behle, T. F., Falci, D. R., Freitas, T., Lopes, N. T., Nunes, M., ... & Zavascki, A. P. (2015). Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. *Journal of Antimicrobial Chemotherapy*, 70(5), 1552-1557.
- Rigatto, M. H., Falci, D. R., Lopes, N. T., & Zavascki, A. P. (2016). Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B. *International journal of antimicrobial agents*, 47(2), 146-150.
- Rigatto, M. H., Vieira, F. J., Antchev, L. C., Behle, T. F., Lopes, N. T., & Zavascki, A. P. (2015). Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with *Acinetobacter baumannii* or *Pseudomonas aeruginosa* infections. *Antimicrobial agents and chemotherapy*, 59(10), 6575-6580.
- Rosales-Reyes, R., Alcántara-Curiel, M. D., Jarillo-Quijada, M. D., Gayosso-Vázquez, C., del Rayo Morfin-Otero, M., Rodríguez-Noriega, E., & Santos-Preciado, J. I. (2016). Biofilm formation and susceptibility to polymyxin B by a highly prevalent clone of multidrug-resistant *Acinetobacter baumannii* from a Mexican Tertiary Care Hospital. *Chemotherapy*, 61(1), 8-14.
- Sandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., ... & Zavascki, A. P. (2013). Population pharmacokinetics of intravenous polymyxin

- B in critically ill patients: implications for selection of dosage regimens. *Clinical infectious diseases*, 57(4), 524-531.
- Schemuth, H., Dittmer, S., Lackner, M., Sedlacek, L., Hamprecht, A., Steinmann, E., ... & Steinmann, J. (2013). In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. *Mycoses*, 56(3), 297-303.
- Schwartz, S. N., Medoff, G., Kobayashi, G. S., Kwan, C. N., & Schlessinger, D. (1972). Antifungal properties of polymyxin B and its potentiation of tetracycline as an antifungal agent. *Antimicrobial agents and chemotherapy*, 2(1), 36-40.
- See comment in PubMed Commons below E. K. Adams, D. S. Ashcrat and G. A. Pankey, Am. J. Med. Sci., vol. 35, pp.265–270, 2016.
- Shaikh, S., Fatima, J., Shakil, S., Rizvi, S. M. D., & Kamal, M. A. (2015). Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi journal of biological sciences*, 22(1), 90-101..
- Sobieszczyk, M. E., Furuya, E. Y., Hay, C. M., Pancholi, P., Della-Latta, P., Hammer, S. M., & Kubin, C. J. (2004). Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. *Journal of Antimicrobial Chemotherapy*, 54(2), 566-569.
- Tam, V. H., Cao, H., Ledesma, K. R., & Hu, M. (2011). In vitro potency of various polymyxin B components. *Antimicrobial agents and chemotherapy*, 55(9), 4490-4491.
- Tam, V. H., Schilling, A. N., Vo, G., Kabbara, S., Kwa, A. L., Wiederhold, N. P., & Lewis, R. E. (2005). Pharmacodynamics of polymyxin B against *Pseudomonas aeruginosa*. *Antimicrobial agents and chemotherapy*, 49(9), 3624-3630.
- Tarquinio, K., Confreda, K., Shurko, J., & LaPlante, K. (2014). Activities of tobramycin and polymyxin E against *Pseudomonas aeruginosa* biofilm-coated medical grade endotracheal tubes. *Antimicrobial agents and chemotherapy*, 58(3), 1723-1729.
- Teo, J., Lim, T. P., Hsu, L. Y., Tan, T. Y., Sasikala, S., Hon, P. Y., ... & Apisarnthanarak, A. (2015). Extensively drug-resistant *Acinetobacter baumannii* in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. *Antimicrobial resistance and infection control*, 4(1), 1-7.
- Thamlikitkul, V., Tiengrim, S., & Seenama, C. (2014). In vitro activity of polymyxin B against carbapenem-resistant *Acinetobacter baumannii*. *J Med Assoc Thai*, 97(12), 1254-8.
- Theuretzbacher, U., Van Bambeke, F., Cantón, R., Giske, C. G., Mouton, J. W., Nation, R. L., ... & Kahlmeter, G. (2015). Reviving old antibiotics. *Journal of Antimicrobial Chemotherapy*, 70(8), 2177-2181.
- Ventola, C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. *Pharmacy and therapeutics*, 40(4), 277.
- Venturini, T. P., Rossato, L., Chassot, F., Keller, J. T., Piasentin, F. B., Santurio, J. M., & Alves, S. H. (2016). In vitro synergistic combinations of pentamidine, polymyxin B, tigecycline and tobramycin with antifungal agents against *Fusarium* spp. *Journal of medical microbiology*, 65(8), 770-774.
- Wei, W., Yang, H., Hu, L., Ye, Y., & Li, J. (2015). Activity of levofloxacin in combination with. *Journal of Microbiology, Immunology and Infection*, 20, 1e10.

- Weinstein, L., Doan, T. L., & Smith, M. A. (2009). Neurotoxicity in patients treated with intravenous polymyxin B: Two case reports. *American Journal of Health-System Pharmacy*, 66(4), 345-347.
- Zavascki, A. P. (2011). Dose adjustment of polymyxins for renal insufficiency. *Antimicrobial agents and chemotherapy*, 55(10), 4940-4940.
- Zavascki, A. P., Goldani, L. Z., Cao, G., Superti, S. V., Lutz, L., Barth, A. L., ... & Li, J. (2008). Pharmacokinetics of intravenous polymyxin B in critically ill patients. *Clinical infectious diseases*, 47(10), 1298-1304.
- Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007). Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. *Journal of antimicrobial chemotherapy*, 60(6), 1206-1215.
- Zeidler, U., Bougnoux, M. E., Lupan, A., Helynck, O., Doyen, A., Garcia, Z., ... & d'Enfert, C. (2013). Synergy of the antibiotic colistin with echinocandin antifungals in *Candida* species. *Journal of Antimicrobial Chemotherapy*, 68(6), 1285-1296,
- Zhai, B., & Lin, X. (2013). Evaluation of the anticryptococcal activity of the antibiotic polymyxin B in vitro and in vivo. *International journal of antimicrobial agents*, 41(3), 250-254.
- Zhai, B., Zhou, H., Yang, L., Zhang, J., Jung, K., Giam, C. Z., ... & Lin, X. (2010). Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. *Journal of Antimicrobial Chemotherapy*, 65(5), 931-938.